GADD45B EXPRESSION IS ASSOCIATED WITH RISK OF BONE METASTASIS IN BREAST CANCER PATIENTS

Abstract

Bone metastatic breast cancer is an uncurable disease. Aproximately 80% of patients with advanced breast cancer develop bone metastasis, and these patients' life expectancy is limited to 2-3 years following diagnosis of bone metastasis. Currently, there is no effective therapy for this condition because of lacking therapeutic targets. Therefore, identifying biomarkers that can be used to diagnose early and prognose of bone metastatic breast cancer is necessary. In this study, we used bioinformatics tools to analyse the expression of GADD45B and its correlation with bone metastasis breast cancer. Our results showed that GADD45B expression correlates with the risk and duration of bone metastasis of breast
cancer. Breast cancer patients with high expression levels of GADD45B had a high risk of bone metastasis and poor bone metastasis-free survival outcomes. GADD45B is an independent biomarker to predict bone metastasis of breast cancer. Elevated expression of GADD45B predicts a poor prognosis in breast cancer patients. GADD45B could be a potential therapeutic target for patients with bone metastatic breast cancer. Taken together, the current results show that GADD45B is a valuable biomarker for improving diagnostic efficiency and prognosis in the age of precision medicine.